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AbsTrACT
background Mass drug administration (MDa) of 20 
mg/kg (maximum 1 g in adults) azithromycin for ocular 
Chlamydia trachomatis (ct) infection is a key component 
of the WHO trachoma elimination strategy. However, 
this dose may be suboptimal in Mycoplasma genitalium 
infection and may encourage emergence of antimicrobial 
resistance (aMr) to azithromycin.
Objectives to determine the effect of MDa for 
trachoma elimination on M. genitalium prevalence, strain 
type and azithromycin resistance.
Methods a secondary analysis of ct-negative 
vulvovaginal swabs from three outpatient antenatal 
clinics (Honiara, Solomon islands) from patients recruited 
either pre-MDa, or 10 months post-MDa in two cross-
sectional surveys was carried out. Swabs were tested 
for M. genitalium infection using Fast track Diagnostics 
Urethritis Plus nucleic acid amplification assay. M. 
genitalium-positive samples were subsequently tested for 
azithromycin resistance by sequencing domain V of the 
23S rrna Dna region of M. genitalium and underwent 
phylogenetic analysis by dual locus sequence typing.
results M. genitalium prevalence was 11.9% 
(28/236) in women pre-MDa and 10.9% (28/256) 10 
months post-MDa (p=0.7467). Self-reported receipt 
of azithromycin as part of MDa was 49.2% in women 
recruited post-MDa and 17.9% (5/28) in those who 
tested M. genitalium positive. Of samples sequenced 
(21/28 pre-MDa, 22/28 post-MDa), all showed a 
macrolide susceptible genotype. Strain typing showed 
that sequence types diverged into two lineages, with a 
suggestion of strain replacement post-MDa.
Conclusion a single round of azithromycin MDa in 
an island population with high baseline M. genitalium 
prevalence did not appear to impact on either prevalence 
or azithromycin resistance, in contrast to reported 
decreased genital ct prevalence in the same population. 
this may be due to limitations such as sample size, 
including ct-negative samples only, and low MDa 
coverage. Further investigation of the impact of multiple 
rounds of MDa on M. genitalium azithromycin aMr 
in antibiotic experienced and naïve populations is 
warranted.
bACkgrOund
Mycoplasma genitalium (MG) is an STI of increasing 
global importance, causing serious maternal and 
child health sequelae.1 2 Management is threatened 
by antimicrobial resistance (AMR) to the first-line 
treatment azithromycin,3 and treatment options are 
limited.4 Trachoma is the leading infectious cause of 
blindness worldwide,5 caused by ocular Chlamydia 
trachomatis (CT) infection. A key component of 
the WHO trachoma elimination strategy is mass 
drug administration (MDA) with 20 mg/kg azith-
romycin, up to a maximum of 1 g in adults. MDA 
is recommended annually for a minimum of 3 years 
in districts where trachoma is endemic (trachoma-
tous inflammation-follicular prevalence ≥10% in 
1–9 year-olds).6 Temporary increases in carriage 
of macrolide-resistant Streptococcus pneumoniae, 
Staphylococcus aureus and Escherichia coli have 
been observed following MDA.7 Thus, while MDA 
with azithromycin may have significant benefits 
through reducing prevalence of active trachoma, 
ocular CT infection,8 genital CT infection9 and 
even child mortality,10 these may be undermined 
by subsequent emergence of AMR in target and 
non-target organisms.
Azithromycin resistance rates vary worldwide, 
with reports of 79.4% in Australia11 12 and over 70% 
in Japan.13 Limited data exist on resistance prev-
alence in Pacific Basin nations. An estimated 12% 
of infected patients treated with 1 g azithromycin 
develop macrolide resistance after treatment14 with 
resistance mediated by single nucleotide polymor-
phisms (SNP) most frequently observed at adeno-
sine nucleotides at positions 2058 and 2059 within 
the 23S rRNA gene.15 Resistance selecting pressures, 
such as mass treatment programmes, may worsen 
this situation. This raises the question of whether 
secondary beneficial impacts of azithromycin 
MDA (reduced morbidity and mortality) should be 
weighed against potential negative impacts (AMR). 
Given the large populations treated with azithro-
mycin by trachoma elimination programmes (over 
800 million doses provided to programmes by the 
International Trachoma Initiative as of December 
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201816), we aimed to ascertain the effect of a trachoma 
programme MDA distribution on MG prevalence and azithro-
mycin resistance.
METhOds
study population
Patient samples and data were collected as described previously.9 
Briefly, women aged 16–49 years attending three community 
antenatal clinics (ANC) in Honiara, Solomon Islands, were 
recruited over 10 days in August 2014. Participants were invited 
to take part pre-MDA. A new group of women aged 16–49 
years was enrolled in the same clinics 10 months post-MDA, 
over 5 days in July 2015. Demographic and clinical data were 
collected by clinic nursing staff. At both time points, two self-
taken vulvovaginal swabs were collected and stored at −20°C in 
the recruiting clinic; one was tested for CT and Neisseria gonor-
rhoeae using the ProbeTec CT/GC assay (Becton Dickinson, 
USA) at the Solomon Islands national reference laboratory, 
while the other was shipped on dry ice to the London School 
of Hygiene and Tropical Medicine (UK) and stored at −20°C. 
Swabs matched to CT-negative samples from reference testing 
were included in this study (CT-positive samples were allocated 
for other research9), and were transported dry on dry ice to St 
George’s, University of London, UK.
Pathogen detection
DNA from swabs was eluted in 1 mL phosphate buffered saline 
(PBS) (Sigma-Aldrich, USA) followed by vortexing for 15 s and 
brief centrifugation. The entire eluate was removed in prepara-
tion for testing. During preparation, one media control sample 
of PBS was included for every 32 samples. DNA extraction was 
carried out by the QIASymphony SP/AS instrument (Qiagen, 
Germany) with the Virus/Pathogen Mini Kit using the Complex 
200 protocol, with a 60 µL elution volume. MG was tested for 
using FTD Urethritis Plus (FTDUP) PCR Kit (Fast-Track Diag-
nostics, Luxembourg) on the Rotor-Gene Q (Qiagen) according 
to manufacturer’s instructions. FTDUP positivity was defined as 
an exponential amplification signal crossing a threshold of 0.05 
normalised fluorescence, as per standard practice at South West 
London Pathology, St George’s University Hospitals NHS Foun-
dation Trust. For a result to be considered valid, (1) the internal 
control had to be positive and have a cycle threshold (Cq) value 
≤33, or if above 33, within ±3.3 Cq of the extraction control’s 
Cq; and (2) positive, media and no-template controls had to 
pass. The person carrying out the testing was blind to all patient 
data, including reference CT/NG test results.
Mg 23s rrnA genotyping
Samples identified as MG positive by FTDUP underwent Sanger 
sequencing of the domain V region of the 23S rRNA gene to 
identify SNPs at positions 2058 and 2059 (E. coli numbering) 
associated with high-level macrolide resistance. Two microli-
tres of extracted DNA was amplified using previously validated 
primers15 using the Multiplex PCR Kit (Qiagen) according to 
manufacturer’s instructions on a GS-1 thermal cycler (G-Storm, 
UK). Pre-MDA samples were amplified as follows: 95°C 15 
min, 45 cycles of 94°C 30 s, 56.5°C 90 s and 72°C 90 s, with a 
final step of 72°C 10 min. Post-MDA samples were amplified as 
follows: 94°C 15 min, 45 cycles of 94°C 30 s, 60°C 3 min and 
72°C 90 s with a final step of 72°C 10 min. If the initial 2 µL of 
extracted DNA used as template failed to generate product, then 
PCR was repeated with 5 µL eluate.
PCR products from pre-MDA samples were analysed by 
Bioanalyzer DNA 1000 Kit (Agilent, USA) and extracted DNA 
samples submitted to Source Bioscience (Cambridge, UK) 
for clean-up and sequencing. Post-MDA PCR products were 
analysed using 2% size select gel on the E-gel system (Thermo 
Fisher, USA). Desired bands were extracted and underwent 
clean-up with MinElute Reaction Cleanup Kit (Qiagen). DNA 
concentrations were assessed using HS DNA Kit on the Qubit 
3.0 (Thermo Fisher) and adjusted to meet the Source Bioscience 
requirements. Sequencing analysis involved alignment to MG 
G37 strain to check for resistance-associated SNPs using Clustal 
Omega software.17 18
strain typing
As there was insufficient DNA for whole genome sequencing 
(WGS), we performed a validated dual locus sequence typing 
(DLST) method.19 Approximately 600 µL of residual swab 
eluate from MG-positive samples underwent DNA extraction 
using FastDNA SPIN Kit and the FastPrep 5G Instrument (MP 
Biomedicals, USA) according to manufacturer’s instructions, with 
the following modification: 600 µL eluate buffer was added to 
600 µL 1% sodium dodecyl sulfate, 60 mM EDTA and 100 mM 
Tris buffer (pH8). DLST was performed using MG191 (mgpB) 
SNP typing combined with analysis of the MG309 variable 
number tandem repeat, as described previously.3 19 20 PCR was 
performed using Multiplex PCR Kit according to manufacturer’s 
instructions. Five microlitres of extracted DNA was used in each 
PCR reaction. If no amplicons were produced, DNA volume was 
increased to 15 µL. PCR was carried out on a T-100 thermo-
cycler (Bio-Rad, USA): 95°C 15 min, 45 cycles of 94°C 30 s, 
58°C 90 s, and 72°C 90 s, and a final extension of 72°C 10 min. 
PCR products underwent processing as described above for MG 
23S rRNA genotyping of post-MDA samples. Where sequences 
were available for both loci for a sample, sequences were concat-
enated and underwent alignment by Clustal Omega.17 18 Phylo-
genetic trees were produced using RaxML21 and figures with 
FigTree V.1.4.3.22
sample size and statistical analysis
Sample size was constrained by the genital CT study design,9 
which aimed to recruit a total of 375 women on the assump-
tion of a change in prevalence from 20% to less than 10%. We 
assumed similar rates of infection and impact for MG. We did 
not anticipate identifying any azithromycin resistance pre-MDA 
due to azithromycin only being recommended for MDA for 
trachoma elimination in the Solomon Islands. Based on an esti-
mated MG prevalence of 10% post-MDA and 12% azithromycin 
resistance development14 between pre-MDA and post-MDA, we 
expected to identify an additional two cases of azithromycin 
resistance post-MDA compared with pre-MDA. Logistic regres-
sion was used to calculate the ORs for factors associated with 
MG infection. Variables tested included patient demographics, 
symptoms, patient-reported previous treatment of other STIs 
and patient-reported receipt of MDA. Patients were not required 
to have a full data set to be included in the analysis and data were 
only excluded where they were missing for calculation of ORs 
(table 1). Analysis was carried out using Stata V.10.1 (StataCorp, 
USA). All sequences in this study have been submitted to 
EMBL-ENA (accession: PRJEB26624).
rEsulTs
Population characteristics
Figure 1 represents the pre-MDA and post-MDA sample flow. 
Table 1 displays the study population characteristics. Among 
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Table 1 Risk factors for Mycoplasma genitalium infection, including demographic data
logistic regression risk factor analysis for being Mg positive pre-MdA and post-MdA
Pre-MdA Post-MdA
univariate analysis univariate analysis
Characteristic
Participants, 
n
With Mg*, 
n (%) Or 95% CI P value
Participants, 
n
With Mg*, 
n (%) Or 95% CI P value
Age group (years) 
  15–24 68 9 (13.2) 1.00 113 13 (11.5) 1.00
  25–34 104 10 (9.6) 0.70 0.27 to 1.82 0.461 114 11 (9.7) 0.82 0.35 to 1.92 0.650
  35–44 39 6 (15.4) 1.19 0.39 to 3.64 0.758 28 4 (14.3) 1.28 0.38 to 4.28 0.686
  45-64† 11 0 (0) – – – 0 0 (0) – – –
  Data 
unavailable
14 1
Clinic 
  K 94 11 (11.7) 1.00 77 10 (13.0) 1.00
  M 64 7 (10.9) 0.93 0.34 to 2.53 0.882 86 12 (14.0) 1.09 0.44 to 2.68 0.857
  R 78 9 (12.0) 1.03 0.40 to 2.63 0.953 92 6 (6.5) 0.47 0.16 to 1.35 0.160
  Data 
unavailable
0 1
Ethnicity 
  Melanesian 212 25 (11.8) 1.00 228 26 (11.4) 1.00
  Other 14 2 (14.3) 1.25 0.26 to 5.90 0.781 24 2 (8.3) 0.71 0.16 to 3.18 0.650
  Data 
unavailable
10 4
Urban/Rural 
  Urban 214 22 (10.3) 1.00 197 23 (11.7) 1.00
  Rural 6 1 (16.7) 1.75 0.19 to 15.63 0.618 46 3 (6.5) 0.53 0.15 to 1.84 0.316
  Data 
unavailable
16 13
Education (years) 
  224 25 (10.7) 1.09 0.99 to 1.19 0.082 255 28 (11.0) 0.94 0.86 to 1.03 0.196
  Data 
unavailable
12 1
Currently married 
  No 37 7 (18.9) 1.00 51 6 (11.8) 1.00
  Yes 192 19 (9.9) 0.47 0.18 to 1.22 0.120 198 21 (10.6) 0.89 0.34 to 2.33 0.813
  Data 
unavailable
7 7
Living with partner 
  No 40 8 (20.0) 1.00 29 4 (13.8) 1.00
  Yes 184 17 (9.2) 0.41 0.16 to 1.02 0.056 217 23 (10.6) 0.74 0.24 to 2.32 0.606
  Data 
unavailable
12 10
STI in last 12 months 
  No 224 25 (11.2) 1.00 229 23 (10.0) 1.00
  Yes 8 2 (25.0) 2.65 0.51 to 13.9 0.247 22 4 (18.2) 1.99 0.62 to 6.39 0.247
  Data 
unavailable
4 5
Symptoms 
  No 188 23 (12.2) 1.00 222 26 (11.7) 1.00
  Yes 37 3 (8.1) 0.63 0.18 to 2.23 0.476 22 1 (4.5) 0.36 0.05 to 2.78 0.327
  Data 
unavailable
11 12
Gonorrhoea positive‡ 
  No 228 25 (11.0) 1.00 240 28 (11.7) 1.00
  Yes 5 2 (40.0) 5.41 0.86 to 33.98 0.072 15 0 (0) – – –
  Data 
unavailable
3 1
TV positive§ 
  Negative 146 14 (9.6) 1.00 135 16 (11.9) 1.00
Continued
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logistic regression risk factor analysis for being Mg positive pre-MdA and post-MdA
Pre-MdA Post-MdA
univariate analysis univariate analysis
Characteristic
Participants, 
n
With Mg*, 
n (%) Or 95% CI P value
Participants, 
n
With Mg*, 
n (%) Or 95% CI P value
  Positive 87 13 (14.9) 1.66 0.74 to 3.71 0.220 120 12 (10.0) 0.83 0.37 to 1.83 0.637
  Data 
unavailable
3 1
Received MDA 
  No N/A N/A N/A N/A N/A 125 22 (17.6) 1.00
  Yes N/A N/A N/A N/A N/A 126 5 (4.0) 0.19 0.07 to 0.53 0.001
  Data 
unavailable
5
Risk factor analysis for M. genitalium (MG) prevalence.
*MG positive defined by FTD Urethritis Plus Kit.
†Age group 45–64 years predicted failure perfectly.
‡Positive by BD ProbeTec and/or FTD Urethritis Plus Kit.
§Positive by FTD Urethritis Plus Kit.
MDA, mass drug administration; N/A, not applicable; TV, Trichomonas vaginalis.
Table 1 Continued
Figure 1 Sample flow. BD, Becton Dickinson; CT, Chlamydia 
trachomatis; FTD, Fast Track Diagnostics; MDA, mass drug 
administration; MG, Mycoplasma genitalium.
Figure 2 Phylogenetic tree of Mycoplasma genitalium-positive 
samples using dual locus sequence typing. Red denotes samples 
collected pre-MDA and blue denotes samples collected post-MDA; 
bootstrap value between MG1 and MG2=100%. Scale: mean number of 
nucleotide substitutions per site. MDA; mass drug administration.
pre-MDA and post-MDA patients included in the analysis, 
38/236 (16.1%) vs 22/256 (8.6%; p=0.011) respectively 
reported having a symptom indicative of an STI (dyspareunia, 
abnormal vaginal discharge or genital ulcer) within the previous 
month. One hundred and twenty-six (49.2%) post-MDA 
patients reported receiving azithromycin as part of MDA; for 
four patients data were unavailable.
Impact of MdA on Mg prevalence and azithromycin 
resistance
No difference was found between pre-MDA and post-MDA 
MG prevalence; 11.9% (95% CI 8.3% to 16.6%; n=28/236) vs 
10.9% (95% CI 7.9% to 15.4%; n=28/256) respectively. Azith-
romycin resistance genotypes were generated for 21/28 women 
pre-MDA and 22/28 women post-MDA (figure 1), no azithro-
mycin resistance-conferring SNPs at the 2058 or 2059 positions 
of 23S rRNA were found at either time point.
risk factors for Mg infection
No risk factors were significantly associated with MG infec-
tion pre-MDA. 17.6% (22/125) of women who reported not 
receiving MDA were found to be MG positive compared with 
4% (5/126) of women who reported receiving MDA (OR of 
being MG positive after MDA receipt: 0.19 [p=0.001]). Despite 
post-MDA women having fewer STI symptoms than pre-MDA 
women, and being more likely to have been treated for an STI in 
the previous 12 months, these factors were not associated with 
reduced likelihood of being MG positive post-MDA.
strain typing
Sequencing was successful for both MG191 and MG309 loci 
for 25/28 pre-MDA and 16/28 post-MDA samples. Sequence 
types diverged into two main lineages: MG1 (n=34) and MG2 
(n=7) (bootstrap value 100%; figure 2). The proportion of 
MG2 lineage samples changed from 1/25 (4%) pre-MDA to 6/16 
(37.5%) post-MDA (p<0.01; Fisher’s exact test), suggesting a 
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degree of strain replacement between the time points. Overall, 
only 5/27 (18.5%) of post-MDA MG-positive patients received 
azithromycin, including only 2/10 MG1 and 0/5 MG2 DLSTs 
of those sequenced. Azithromycin treatment status was not 
available for one woman with MG2 strain type post-MDA. No 
other bootstrap values between individual MG infections were 
sufficiently high to confidently separate strains to any higher 
resolution.
dIsCussIOn
In this secondary analysis of ANC attendees in the Solomon 
Islands, we found no change in prevalence of MG infection nor 
appearance of 23S rRNA genotypic markers of azithromycin 
resistance in the interval from before to 10 months after a single 
round of azithromycin MDA for trachoma elimination. We also 
demonstrated azithromycin receipt during MDA was associated 
with reduced likelihood of post-MDA MG positivity. A change in 
composition of MG strain types in those sampled was observed 
between pre-MDA and post-MDA patients.
Factors that may affect impact of MDA on STI transmission 
include antibiotic efficacy and treatment failure, MDA coverage 
especially in high STI-risk and STI-burdened populations and 
infection persistence. Contributions of these factors to reducing 
STI prevalence through direct treatment, or longer term by 
decreasing onward transmission, need to be considered in rela-
tion to the time period of MDA impact assessment.
Importantly, azithromycin receipt as part of the MDA was 
reported in only 49.2% of women post-MDA. Programme MDA 
coverage estimates are often unreliable as coverage is mostly 
calculated by doses given divided by estimated resident popula-
tion, determined at the most recent census23; the denominator 
may be out of date or otherwise unrepresentative of the popula-
tion present at the time of MDA. Furthermore, MDA coverage 
data are generally not available by age and sex. It was there-
fore not possible to compare MDA receipt between the study 
and wider populations. Neither data regarding sexual history 
between MDA receipt and study recruitment nor MDA receipt 
among sexual partners were collected. These data could have 
provided insight into potential reinfection risk and an explana-
tion for why MG prevalence was unchanged between pre-MDA 
and post-MDA populations. The study was performed as two 
independent cross-sectional surveys within three ANCs, patients 
of which are perhaps at a different STI risk level than the 
general population. Importantly, sample size was determined 
by the genital CT study design, and therefore may not have 
been sufficient for detecting smaller overall prevalence changes 
or azithromycin resistance emergence. If the five MG-positive 
women who had reported MDA receipt post-MDA were positive 
because of persistence of infection following failure of azithro-
mycin to cure infection, one might expect some of these to have 
developed azithromycin resistance. As no resistance-associated 
mutations were detected this would suggest that these patients 
were most likely infected post-MDA, consistent with high rates 
of transmission in the population and may also explain the high 
prevalence of infection. It was not possible to sequence a propor-
tion of the MG-positive samples (7/28 [25%] pre-MDA; 6/28 
[21.4%] post-MDA) for 23S mutations, and it is possible that 
these samples contained macrolide-resistant strains. It cannot be 
discounted that those we were unable to sequence were not true 
positives. Unfortunately, there are no published sensitivity and 
specificity data on FTDUP performance for detection of MG 
sensitivity and specificity. In another body of work we found 
FTDUP sensitivity to be 100% and specificity to be 95.8%, albeit 
in a limited sample size of 122 (unpublished data). Therefore, 
we do not consider test performance to potentially be a major 
limiting factor in correctly identifying MG-positive and negative 
samples. Finally, it was not possible to test CT positives for MG, 
due to their allocation to another study, which may have led to an 
underestimate of MG positivity both pre-MDA and post-MDA 
given that coinfection with CT and MG is common.24–26 Addi-
tionally, as a significant reduction in CT prevalence was found 
in the primary analysis, exclusion of CT positives (n=103, 
pre-MDA n=60, post-MDA n=43) may be a source of bias as 
a greater proportion of CT positives was excluded from the 
pre-MDA samples versus the post-MDA samples.
Despite these limitations, our risk factor analysis provides 
strong evidence that those receiving azithromycin MDA had 
reduced odds of being MG positive, implying that increasing 
MDA coverage may be key in achieving greater MG prevalence 
impact, at least in the short term. Significant scope for increasing 
MDA uptake in this population exists as only 49.2% of women 
recruited post-MDA reported azithromycin receipt. Post-MDA 
enrolment occurred approximately 10 months after baseline, 
making it unlikely that women enrolled at this time point would 
have been pregnant during MDA, an explanation that might 
otherwise account for low azithromycin uptake. However, we 
cannot discount the possibility that some women avoided MDA 
through fear of taking treatment while trying to conceive. It is 
unclear whether 10 months post-MDA is the most appropriate 
time point to measure MDA impact on prevalence, as any initial 
MG prevalence reduction may have waned by 10 months. In 
remote island populations, this might be expected to occur if 
there were relatively high rates of sexual transmission of endog-
enous, rather than imported, MG infection. More data on trans-
mission dynamics and STI epidemiology within the Solomon 
Islands would help to establish the most appropriate time points 
for measuring MDA impact on STI prevalence.
These data may also help identify factors associated with MG 
infection. Our risk factor analysis did not identify any factors 
other than self-reported MDA receipt, despite high prevalences 
pre-MDA (11.9%) and post-MDA (10.9%). This may be due to 
the relatively small sample size, or the variables collected not 
including factors that are important MG infection correlates in 
this population. Risk factor analyses are useful in helping target 
prevention and control strategies and interventions, but there 
are limited data on MG prevalence in pregnant women. The 
high prevalence of CT and N. gonorrhoeae previously reported9 
and MG in our study, both pre-MDA and post-MDA, indicates 
that this population would benefit from effective STI prevention 
strategies. Further epidemiological investigations in different 
population groups are warranted to help develop, monitor 
and evaluate these strategies, including assessing associations 
between MG infection and adverse pregnancy outcomes.
It is possible that single-dose azithromycin used during MDA 
was not as effective against MG as against CT, explaining the 
lack of overall impact on MG prevalence. MG cure rates with 
1 g azithromycin are known to be as low as 81%, independent 
of pre-existing macrolide resistance,27 much lower than CT cure 
rates.28 However, as strong evidence existed of reduced likeli-
hood of being MG positive in those who reported MDA receipt, 
we do not believe this to be a major explanation for our results.
We were unable to perform WGS for strain typing because 
of insufficient DNA. However, WGS for MG has not yet been 
validated for phylogenetic analysis, with concerns raised about 
degrees of genome recombination.29 Using DLST, we identified 
two major strain lineages, as well as detected an increase in MG2 
proportion post-MDA. This shift might have occurred due to 
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key messages
 ► First study to investigate the impact of mass drug 
administration (MDA) for trachoma elimination on 
Mycoplasma genitalium prevalence and azithromycin 
resistance.
 ► In this Solomon Islands’ antenatal care population, MDA 
with self-reported coverage of approximately 50% did not 
appear to impact M. genitalium prevalence or azithromycin 
resistance.
 ► However, in those who reported receiving azithromycin 
as part of MDA, we found reduced odds of M. genitalium 
infection.
 ► Overall, there was evidence suggestive of M. genitalium 
strain replacement following MDA.
differences in characteristics of infection such as bacterial load, 
leading to variable antibiotic susceptibility,30 which may intro-
duce sequencing bias. No post-MDA patients with MG2 and 
only 2/10 with MG1 reported receiving azithromycin, suggesting 
low likelihood of strain replacement occurring directly because 
of azithromycin receipt. However, it is possible that MDA effects 
on strain representation in the general population may have been 
transmitted to the ANC population. Whether this is measurable 
10 months after MDA is questionable and other factors, such 
as natural bacterial evolution, changes in sexual networks over 
time, or stochastic changes in a relatively small effective popula-
tion size, may account for these findings.
Absence of azithromycin resistance in MG in the Solomon 
Islands contrasts with high resistance prevalence in other parts 
of the Western Pacific Region, namely Australia and Japan.31 32 
The Solomon Islands has low azithromycin usage, with MDA for 
trachoma elimination being the only recommended use within 
the country at the time of MDA. In contrast, in other, especially 
high-income, countries, azithromycin is indicated for a number 
of conditions, including respiratory infections.33 MG has only 
one 23S rRNA locus making it particularly susceptible to selec-
tion of resistant strains, which occurs in approximately 12% 
of treated patients.14 Cure rates are observed to decline where 
1 g is part of the national standard for STI treatment.14 30 We 
may therefore have expected to observe an increased prevalence 
of azithromycin resistance markers being selected given MDA 
coverage. However, relatively low coverage in the ANC popula-
tion combined with relatively low sample size may explain why 
we did not detect emergent AMR. It is possible that repeat MDA 
rounds may select for resistance through increased selection 
pressure, undermining the possible benefits of actual receipt of 
azithromycin during MDA that we observed in this round. More 
studies focusing on general populations and over multiple MDA 
rounds would more fully evaluate the risk of STI AMR develop-
ment following MDA.
In this first study, assessing the impact of a single round of 
azithromycin MDA for trachoma elimination on MG prevalence 
and AMR among ANC attendees in an island population, we 
did not detect reduction in MG prevalence nor the appearance 
of azithromycin resistance following a single round of MDA with 
1 g azithromycin for trachoma elimination. However, receipt 
of azithromycin was associated with reduced odds of being MG 
positive post-MDA. A number of factors may account for these 
findings, including low MDA coverage, high reinfection risk from 
untreated partners, insufficient sample size, time gap between 
pre-MDA and post-MDA sample collection and perhaps a lack 
of 1 g azithromycin efficacy for treatment of MG. These findings 
cannot otherwise be confidently explained by an observed change 
in strain representation between pre-MDA and post-MDA sample 
sets. Benefits of MDA for trachoma elimination, and in national 
programmes for other neglected tropical diseases, must continue to 
be weighed against potential negative consequences, such as AMR 
emergence. Further investigation of the impact of multiple rounds 
of azithromycin MDA on MG prevalence and AMR in different 
populations and settings is warranted.
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